دورية أكاديمية

Association of isoproterenol infusion during catheter ablation of atrial fibrillation with outcomes: insights from the UC San Diego AF Ablation Registry

التفاصيل البيبلوغرافية
العنوان: Association of isoproterenol infusion during catheter ablation of atrial fibrillation with outcomes: insights from the UC San Diego AF Ablation Registry
المؤلفون: Aldaas, Omar M., Darden, Douglas, Mylavarapu, Praneet S., Han, Frederick T., Hoffmayer, Kurt S., Krummen, David, Ho, Gordon, Raissi, Farshad, Feld, Gregory K., Hsu, Jonathan C.
المصدر: Journal of Interventional Cardiac Electrophysiology ; volume 66, issue 5, page 1243-1252 ; ISSN 1572-8595
بيانات النشر: Springer Science and Business Media LLC
سنة النشر: 2022
مصطلحات موضوعية: Physiology (medical), Cardiology and Cardiovascular Medicine
الوصف: Background High-dose isoproterenol infusion is a useful provocative maneuver to elicit triggers of atrial fibrillation (AF) during ablation. We evaluated whether the use of isoproterenol infusion to elicit triggers of AF after ablation is associated with differential outcomes. Methods We performed a retrospective study of all patients who underwent de novo radiofrequency catheter ablation of AF enrolled in the University of California, San Diego AF Ablation Registry. The primary outcome was freedom from atrial arrhythmias on or off antiarrhythmic drugs (AAD). Results Of 314 patients undergoing AF ablation, 235 (74.8%) received isoproterenol while 79 (25.2%) did not. Among those who received isoproterenol, 11 (4.7%) had additional triggers identified. There were no statistically significant differences in procedure time ( p = 0.432), antiarrhythmic drug use ( p = 0.289), procedural complications ( p = 0.279), recurrences of atrial arrhythmias on or off AAD [adjusted hazard ratio (AHR) 0.92 (95% CI 0.58–1.46); p = 0.714], all-cause hospitalizations [AHR 1.00 (95% CI 0.60–1.67); p = 0.986], or all-cause mortality [AHR 0.14 (95% CI 0.01–3.52); p = 0.229] between groups. Conclusions In this registry analysis, use of isoproterenol is safe but was not associated with a reduction in recurrence of atrial arrhythmias.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1007/s10840-022-01448-x
DOI: 10.1007/s10840-022-01448-x.pdf
DOI: 10.1007/s10840-022-01448-x/fulltext.html
الإتاحة: https://doi.org/10.1007/s10840-022-01448-xTest
حقوق: https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test
رقم الانضمام: edsbas.DAF2E874
قاعدة البيانات: BASE